109 filings
Page 2 of 6
8-K
kq2zrm
18 Apr 23
Regulation FD Disclosure
8:00am
8-K
y6c5m86c
15 Mar 23
Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
4:05pm
8-K
rzpj0vxv
30 Jan 23
Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
4:00pm
8-K
8vplfykr
12 Jan 23
Regulation FD Disclosure
6:59am
8-K
7cebqrgjbjlztrfant
29 Dec 22
Regulation FD Disclosure
7:00am
8-K
9uy5s7ih9p
14 Nov 22
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
q6xprw0v5whea
2 Nov 22
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
4:05pm
8-K
u8qx00t755i2bu
21 Oct 22
Matinas BioPharma Announces Positive Interim Data from the Phase 2
7:00am
8-K
vij26yw3ugk3vexie5
13 Sep 22
Regulation FD Disclosure
7:00am
8-K
5tk8u
11 Aug 22
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
6:25am
8-K
78sye0qwb uwp
12 May 22
Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
6:30am
8-K
tpck7
13 Apr 22
Regulation FD Disclosure
8:43am
8-K
giupd
11 Apr 22
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
7:00am
8-K
bs5tp5zimqlsfner7
8 Mar 22
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
6:30am
8-K
wynrnmuc dv
25 Jan 22
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
6:30am
8-K
fakio1zi j93m3
16 Dec 21
Regulation FD Disclosure
6:30am
8-K
uohq5uj2v 3sie
6 Dec 21
Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
6:30am
8-K
066 hvul14
8 Nov 21
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
6:35am
8-K
r2ch2u61duvse
1 Nov 21
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
6ogpoeax
20 Sep 21
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
7:05am